Craig P Eagle

US Patent:

20120263677, Oct 18, 2012

Filed:

Mar 9, 2012

Appl. No.:

13/416494

Inventors:

Craig J. Eagle - New York NY, US
H. Craig Dees - Knoxville TN, US
Eric A. Wachter - Oak Ridge TN, US
Jamie Singer - Knoxville TN, US

International Classification:

A61K 31/352
A61K 38/20
A61K 38/21
A61K 38/18
A61K 39/00
A61K 39/245
A61K 31/506
A61K 31/5377
A61K 38/17
A61K 31/7088
A61K 31/517
A61K 31/5685
A61K 35/12
A61P 35/00
A61P 37/02
A61P 37/04
A61P 35/04
A61K 39/395

US Classification:

424 852, 4241421, 424 857, 424 855, 424 851, 4241841, 4241991, 4241741, 514454, 4241331, 51425219, 5142345, 514 193, 514 44 R, 51426622, 514171, 424 937, 424 854, 4242771

Abstract:

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.